Introduction: The interaction of immune cells and cancer cells shapes the immunosuppressive tumor microenvironment. For successful cancer immunotherapy, comprehensive knowledge of antitumor immunity as a dynamic spatiotemporal process is required for each individual patient. To this end, we developed an immunogram for the cancerimmunity cycle by using next-generation sequencing.
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refractory malignancies, including lung cancers, has opened new avenues for cancer treatment. [1] [2] [3] [4] [5] However, response rates are still unsatisfactory, with clinical responses usually achieved in only a fraction of patients. Expression of programmed death ligand 1 in the tumor, or its neoantigen load, has been reported to be associated with response to checkpoint blockade therapy and prognosis to some extent, [4] [5] [6] but this information is insufficient for distinguishing between those patients who will respond to therapy and those who should be offered alternative treatments. 7, 8 Therefore, efficient and reliable biomarkers are urgently required.
The evaluation of antitumor immune responses in each individual patient is viewed as a crucial dynamic spatiotemporal process proposed by Chen and Mellman to be a cancer-immunity cycle (CIC) consisting of seven steps: (1) release of cancer antigens, (2) cancer antigen presentation, (3) priming and activation, (4) trafficking of T cells to tumors, (5) infiltration of T cells into tumors, (6) recognition of cancer cells by T cells, and (7) killing of cancer cells. 9 To develop efficient and reliable methods for evaluating antitumor immune responses, several strategies, including flow cytometry, immunohistochemistry (IHC), and transcriptome analysis using microarrays or next-generation sequencing, can be applied. One example using IHC is an immunoscore. [10] [11] [12] In the case of colorectal cancer, an immunoscore based on assessment of the tumor-infiltrating lymphocytes is closely associated with better prognosis than the current TNM classification is. [10] [11] [12] Large-scale genomics data sets of different tumors are now available for extensive analysis of the genetic landscape of tumors. [13] [14] [15] [16] [17] [18] [19] Prognostic immune cells and genes have been reported by extensive review of gene profile studies and computational analyses of large scale genomic data sets. 13, 19 It has been reported that increased expression of genes related to cytotoxic activity in the local tumor microenvironment is also associated with increased expression of those related to immunosuppression. 17, 18 Comprehensive analysis of various functional pathways and molecular networks contribute to uncover the integrated mechanisms of tumor-immune interactions.
These advances in sophisticated analytical methods now allow "omics" data to be generated for each individual patient. In practice, omics data themselves are still a challenge for clinicians to deal with, such that it may be said that there is a compelling need for the development of a "translator" for converting cumbersome omics data into easily comprehensible information for clinical use.
Recently, Blank et al. proposed the concept of the cancer immunogram to visualize general and local cancer immunity status in each patient. 20 In their perspectives article, the concept was applied theoretically to patients but not tested in practice. To accomplish this, here we have developed an immunogram reflecting the CIC and have applied it to real patients with lung cancer. We discuss its potential application for tailoring effective personalized cancer immunotherapy to the individual patient.
Materials and Methods

Patient Selection and Characteristics
Twenty patients with NSCLC who underwent lung resection were included in the study after written informed consent had been obtained. Twelve patients had adenocarcinoma (AD), seven had squamous cell carcinoma (SQ), and one had large cell neuroendocrine carcinoma (LCNEC) ( Table 1) . None of the patients had received any preoperative treatment. Among the 12 patients with AD, seven were found to have EGFR mutations; no anaplastic lymphoma receptor tyrosine kinase gene (ALK) rearrangements were detected. The study was conducted with the approval of the Human Genome and Gene Analysis Research Ethics Committee of the Faculty of Medicine and Graduate School of Medicine of The University of Tokyo and The University of Tokyo Hospital (G3545).
Application of Whole Exome Sequencing and RNA Sequencing
Sequencing libraries of DNA and RNA from tumor and normal tissue samples were prepared as described in Supplementary Data 1 (Supplementary Method 1) , and the enriched sequencing libraries were analyzed by massively parallel sequencing on a HiSeq 1500 sequencer (Illumina, San Diego, CA). Sequence data were processed and utilized for calling somatic missense mutations and expression analyses. Expression values were calculated as fragments per kilobase of transcript per million fragments mapped (FPKM).
Identification of Candidate Neoantigens and Cancer Germline Antigen Expression
Candidate neoantigens were identified as previously described. 21 In brief, four-digit human leukocyte antigen (HLA) class I alleles of each patient were identified from whole exome sequencing data of normal lung tissue or peripheral blood mononuclear cells by using Omixon Target HLA Typing (Omixon, Cambridge, MA). 22 The Immune Epitope Database analysis resource tool NetMHCpan (version 2.8) was used to predict binding affinities of 8-mer to 11-mer mutant peptides to the patients' major histocompatibility complex, class I, A gene (HLA-A); major histocompatibility complex, class I, B gene (HLA-B); and major histocompatibility complex, class I, C gene (HLA-C) alleles. 23, 24 Peptides derived from somatic mutations with a predicted concentration that inhibits 50% value less than 500 nM were considered candidate neoantigens. In this study, we also used RNA sequencing (RNA-Seq) expression data (FPKM > 1) to filter neoantigens accompanying tumor expression.
A list of cancer germline (CG) antigens including 276 genes was obtained from the Cancer Immunity Cancer/ Testis Gene Database (http://www.cta.lncc.br/) in May 2016. 25 A total of 103 genes that had an FPKM value of 0 in the RNA-Seq data of all six normal lung tissue samples were included in the analysis. CG antigens with an FPKM value greater than 1 were analyzed for their capacity to bind to HLA molecules by using the NetMHCpan tool. CG antigens generating peptides with predicted concentration that inhibits 50% values less than 500 nM were considered immunogenic CG (imCG) antigens; the number of these in each patient was counted.
Gene Expression Analysis with RNA-Seq Data
Gene set enrichment analysis (GSEA) was used to estimate whether immune cells were overrepresented in the tumor microenvironment, as previously described. 26, 27 In brief, the expression levels of each gene (FPKM values) were z score-normalized across all samples (20 tumor samples and six normal lung tissue samples). For each tumor, all genes were then ranked in descending order according to their z scores. GSEA PreRanked was used with the default parameters, and the association with each immune cell gene set was represented by a normalized enrichment score (NES). The immune metagene list provided by Angelova et al. was used. 27 For activated dendritic cells (DCs), a gene set provided by Newman et al. (LM22) was used. Table 1 ). An immune cell type was considered significantly enriched or poorer in a tumor when the false discovery rate (q value) was 10% or less.
When an appropriately validated gene set for GSEA was unavailable, a panel of immune-related genes reflecting each step of the CIC was created. 9 RNA-Seq data expression profiles for each gene (FPKM) were transformed into log2 fold changes by using the mean expression of six normal samples as the control.
IHC
IHC analysis was performed on formalin-fixed paraffin-embedded tissue sections for assessment of infiltration of T cell and regulatory T cells (Tregs) by using polyclonal rabbit anti-human CD3 antibody (Dako, Carpinteria, CA), monoclonal mouse anti-human CD8 (clone C8/144B [Dako]), and monoclonal mouse antihuman forkhead box P3 (FOXP3) antibody (clone 236A/E7 [AbCam, Cambridge, United Kingdom]). The slides were counterstained with hematoxylin. Images were captured with a BIOREVO-9000 fluorescence microscope (Keyence, Osaka, Japan); the positively stained area was quantified digitally with BZ-II Analyzer image analysis software (Keyence).
Statistical Analysis
Spearman's correlation test was used to compare NESs obtained by GSEA and IHC-stained areas. Neoantigen load and imCG antigen load were analyzed with two-tailed 
Results
An Immunogram for the CIC
To evaluate the dynamic process of antitumor immunity in an individual patient and formulate strategies to manipulate antitumor immunity for cancer treatment, we developed an immunogram for the CIC. In Figure 1 , the seven steps of the CIC are depicted by the eight axes of the immunogram score (IGS) as follows: IGS 1 , existence of T-cell immunity in the tumor; IGS 2 , tumor antigenicity; IGS 3 , priming and activation; IGS 4 , trafficking and infiltration; IGS 5 , recognition of tumor antigens; and IGS 6 to IGS 8 , suppressive factors preventing killing of cancer cells. Because the CIC depicts dynamic process for the development of antitumor T-cell immunity, assessment of T-cell immunity was set as the first axis of the immunogram for the cancer-immunity cycle.
IGS 1 : Antitumor T-Cell Immunity
First, we investigated the presence of T cells in the tumor by GSEA (Fig. 2) . 26 The NES of 86 genes 27 comprising a T-cell signature was calculated by GSEA in 20 patients. Examples of enrichment plots for patient LK071 obtained by GSEA are shown in Supplementary Data 3 ( Supplementary Fig. 1 ). In all, nine patients had a T-cell-inflamed (T-cell-rich) phenotype with significant enrichment of T cells (q value < 0.1) (see Fig. 2 ).
Detailed results of tumor-infiltrating lymphocyte enrichment analysis by GSEA are shown in Supplementary Data 4 (Supplementary Table 2 ). Of the remaining 11 patients, who were classified as having a non-T-cell-inflamed phenotype, six showed significantly poorer T-cell infiltration (q < 0.1) and the other five were classified as having an intermediate phenotype. Table 3 ). IHC staining of representative patients with either enriched or poor T-cell infiltration are shown in Supplementary Data 6 ( Supplementary Fig. 2 ).
For plotting the immunogram, the NES of T cells in each patient was converted into a z score and then converted into the IGS. If M represents the mean NES and SD represents the standard deviation of the NES, the z score of each patient is calculated as Z ¼ (NES -M)/SD, where Z is the z score.
We then defined the score of the first axis of the immunogram (IGS 1 ) in each patient as
This formula was applied for all axes of the patient's immunogram. The lower and upper limits of the IGS were set at 1 and 5. By definition, IGS ¼ 3 represents an NES equivalent to the mean NES, and IGS ¼ 4.5 or IGS ¼ 1.5 represent NES equivalent to the mean plus 1 SD or mean minus 1SD. The IGS was defined in this way so that patients would be well distributed over the range from 1 to 5. The IGS calculation for patient LK071 is shown as an example in Supplementary Data 7 (Supplementary Method 2).
IGS 2 : Tumor Antigenicity
Tumor antigenicity was evaluated by the number of candidate neoantigens and imCG antigens (Fig. 3A) . Numbers of candidate neoantigens and imCG antigens are shown in Supplementary Data 8 (Supplementary Table 4 ). The median neoantigen load was 23 (range 3-183) in T-cell-inflamed and 71 (range 31-301) in non-T-cell-inflamed tumor (p ¼ 0.053, Welch's t test on log-transformed data). The median imCG antigen load was 1 (range 0-11) in T-cell-inflamed and 4 (range 1-29) in non-T-cell-inflamed tumors (p ¼ 0.14). The number of neoantigens and imCG was summed to give the number of putative cancer antigens to be plotted on the second axis of the immunogram (IGS 2 ) after the z score was calculated, and it was converted to IGS by the same formula as for the first axis (see Fig. 3A ).
IGS 3 : T-Cell Priming and Activation
Antigen presentation and T-cell priming was evaluated by analysis of gene signatures for activated DCs. The enrichment analysis of activated DCs was performed by using 53 genes 28 and the NES was determined (Fig. 3B) . 26, 27 Detailed results of activated DC enrichment analysis by GSEA are shown in Supplementary Data 4 (Supplementary Table 2 ). Activated DCs were significantly enriched in 11 patients (q < 0.1), all of whose tumors were of the T-cell-rich (LK001, LK013, LK047, LK051, LK053, LK066, LK070, and LK071) or intermediate phenotype (LK029, LK059, and LK075). The IGS of the third axis (IGS 3 ) was calculated in the same manner as the first axis.
IGS 4 : Trafficking and Infiltration of T Cells into Tumors
Because there is no established gene set that is suitable for GSEA of T-cell trafficking and infiltration, expression variance was analyzed for each of the genes thought to be positively associated with T-cell trafficking and infiltration. On the basis of a previous report, 9 C-X-C motif chemokine ligand 9 gene (CXCL9), C-X-C motif 27 is shown. Independently, a normalized enrichment score (NES) of 86 T-cell signature genes was calculated by gene set enrichment analysis. 26, 27 First, expression levels of each gene (FPKM) obtained by RNA sequencing were z scorenormalized across all samples (20 tumor samples and six normal lung tissue samples); for each tumor, all genes were then ranked in descending order according to their z scores and an NES of the T-cell signature was calculated for each patient. Again, the NES was z score-normalized across 20 patients and IGS 1 was calculated by the formula IGS 1 ¼ 3 þ 1.5 Â Z, where Z is the z score of NES. Nine patients had a T-cell-inflamed (T-cell-rich) phenotype with significant enrichment of T cells (q value < 0.1). Of the remaining 11 patients, who were classified as having the non-T-cell-inflamed phenotype, six showed significantly poor T-cell infiltration (q < 0.1) and the rest were classified as having the intermediate phenotype. Table 2 ). The number of genes whose expression was up-regulated with log 2 FC > 1 was counted and converted to a z score, after which the IGS 4 was calculated.
IGS 5 : Recognition of Cancer Cells by T Cells
Recognition of cancer cells by T cells requires that the antigen processing and presentation machinery of cancer cells be intact. Therefore, a gene signature for antigen processing and presentation machinery was used for evaluation of the fifth axis of the immunogram (Fig. 4B) . These genes are in general expressed in normal cells; however, some tumors lack or down-regulate their expression, making them invisible to T cells. Therefore, the number of down-regulated genes with log 2 FC less than 0 was counted and converted to a z score. The IGS was calculated as IGS 5 [ 3 -1.5 Â Z, where Z is the z score. Note that a high IGS 5 implies that the number of down-regulated genes is low 5 , immune checkpoint expression for IGS 7 , and other inhibitory molecules for IGS 8 . (A) Expression profiles of genes related to trafficking and infiltration are shown. 9 Fragments per kilobase of transcript per million fragments mapped values from RNA sequencing were compared with the mean fragments per kilobase of transcript per million fragments mapped value of six normal lung tissue samples and displayed as fold change (FC). The z scores of the number of up-regulated genes with log 2 FC > 1 were calculated and then converted to IGS 4 . (B) The z scores of the number of down-regulated (log 2 FC < 0) genes related to antigen presentation machinery were calculated and then converted to IGS 5 . The z scores of the number of up-regulated (log 2 FC>1) genes related to immune checkpoint and other inhibitory molecules were calculated 9 and then converted to IGS 7 (C) and IGS 8 (D). CXCL9, C-X-C motif chemokine ligand 9 gene; CXCL10, C-X-C motif chemokine ligand 10 gene; CCL5, C-C motif chemokine ligand 5 gene; CX3CL1, C-X3-C motif chemokine ligand 1 gene; LFA1, lymphocyte function-associated antigen 1 gene; ICAM1, intercellular adhesion molecule 1 gene; SELE, selectin E gene; HLA-A, major histocompatibility complex, class I, A gene; HLA-B, major histocompatibility complex, class I, B gene; HLA-C, major histocompatibility complex, class I, C gene; B2M, beta-2-microglobulin gene; TAP1, transporter 1, ATP binding cassette subfamily B member gene; TAP2, transporter 2, ATP binding cassette subfamily B member gene; PD-1, programmed cell death 1 gene; BTLA, B and T lymphocyte associated gene; TIM-3, hepatitis A virus cellular receptor 2 gene; LAG3, lymphocyte activating 3 gene; CTLA4, cytotoxic T-lymphocyte associated protein 4 gene; PD-L1, programmed death ligand 1 gene; VISTA, V-set immunoregulatory receptor gene; IL10, interleukin-10 gene; IDO1, indoleamine 2,3-dioxygenase 1 gene; TGFB1, transforming growth factor b1 gene; ARG1, arginase 1 gene; INOS, inositol-3-phosphate synthase 1 gene; CTNNB, catenin beta 1 gene. and the antigen processing and presentation machinery is intact.
IGS 6 to IGS 8 : Killing of Cancer Cells
The effector function of T cells and killing of cancer cells are influenced by the complex interaction of inhibitory cells and molecules. We divided this process into three axes for the immunogram: IGS 6 for the absence of inhibitory cells, IGS 7 for the absence of checkpoint molecule expression, and IGS 8 for the absence of other inhibitory molecules.
As shown in Figure 3C , the infiltration of inhibitory immune cells, such as myeloid-derived supporessor cells (MDSCs) and Tregs, was evaluated by using GSEA. 26 Fig. 2 ) and all such data are shown in Supplementary Data 5 (Supplementary Table 3 ). The sum of the NES for Tregs and MDSCs was calculated and then converted to a z score. Enrichment of these cells suggests an immunosuppressive microenvironment in the tumor. Thus, the sixth axis of the immunogram (IGS 6 ) was calculated as IGS 6 [ 3 -1.5 Â Z, where Z is the z score.
Low IGS 6 suggests that antitumor immunity is suppressed by the infiltration of inhibitory immune cells; absence of inhibitory immune cells results in high IGS 6 .
IGS 7 : Absence of Checkpoint Molecule Expression
It is known that antitumor T-cell responses are inhibited by arrays of immune checkpoint molecules in the tumor microenvironment. For the seventh axis of the immunogram (IGS 7 ), we selected a set of genes for immune checkpoints comprising programmed cell death 1 gene (PD-1), B and T lymphocyte associated gene (BTLA), hepatitis A virus cellular receptor 2 gene (TIM-3), lymphocyte activating 3 gene (LAG3), cytotoxic T-lymphocyte associated protein 4 gene (CTLA4), programmed death ligand 1 gene (PD-L1), and V-set immunoregulatory receptor gene (VISTA), which are expressed on T cells, tumor cells, or antigen-presenting cells (Fig. 4C) . 9 Genes with log 2 FC > 1 were considered to be up-regulated; they were counted and the result was converted to a z score. Thus, the seventh axis of the immunogram (IGS 7 ) was calculated as IGS 7 [ 3 -1.5 Â Z, where Z is the z score. High expression of checkpoint molecules results in low IGS 7 .
IGS 8 : Absence of Other Inhibitory Molecules
Tumor cells and infiltrating cells express a variety of inhibitory molecules that impair the effector function of T cells. Among these, interleukin-10 gene (IL10), indoleamine 2,3-dioxygenase 1 gene (IDO1), transforming growth factor b1 gene (TGFB1), arginase 1 gene (ARG1), inositol-3-phosphate synthase 1 gene (INOS), and catenin beta 1 gene (CTNNB1) were selected for the gene set for IGS 8 , because therapeutic inhibition of these molecules may enhance T-cell immunity. 9 Expression profiles of these inhibitory molecules were evaluated and IGS 8 was calculated likewise (Fig. 4D) .
Interpretation of Immunograms for the CIC
As already described, each step of the CIC was assessed, normalized, and scored onto the eight axes of the immunogram (IGS [1] [2] [3] [4] [5] [6] [7] [8] ) generated for each individual patient by integration onto a radar chart (Fig. 5A-C) . Immunograms of patients with T-cell-rich, intermediate, or T-cell-poor phenotypes displayed distinct features for each IGS (Fig. 5D) . In patients with a T-cell-rich phenotype, high IGS 1 (existence of putative T-cell immunity in the tumor) was accompanied by a high IGS 3 (activation of DCs), high IGS 4 (trafficking and infiltration), and high IGS 5 (likely intact recognition of tumor antigens by T cells), whereas IGS 6 , IGS 7 , and IGS 8 were all low, suggesting increased recruitment of Tregs and MDSCs and up-regulated expression of checkpoint molecules and immunoinhibitory molecules in the tumor. In contrast, in patients with a T-cell-poor phenotype, IGS 1 , IGS 3 , IGS 4 , and IGS 5 were quite low, whereas IGS 2 , IGS 6 , IGS 7 , and IGS 8 were maintained. Activation of DCs was impaired, even if the tumors had relatively high antigenicity. These tumors had recruited few immunosuppressive cells and lacked the expression of immune checkpoint molecules and immunoinhibitory molecules. Each axis of the immunogram from patients with an intermediate phenotype largely showed values lying between the two aforementioned extremes. Interestingly, immunograms for patients with AD could display either a T-cell-rich or T-cell-poor phenotype irrespective of EGFR mutational status. Similar results were obtained in patients with nonadenocarcinoma tumors (Fig. 5E) . These results suggest that histologic type does not necessarily reflect the cancer-immunity status of the tumor.
Discussion
Since the approval of the PD-1 monoclonal antibodies nivolumab and pembrolizumab for treatment of NSCLC, robust and durable responses have been observed, but only 20% to 30% of patients have responded to the therapy. [3] [4] [5] Although the expression of PD-L1 or the number of tumor neoantigens has been reported to Table 2 ).
correlate with treatment outcome, 4-6 better predictive biomarkers for selecting patients who would or would not respond to therapy is warranted. Anticancer immunity is a dynamic process described as a CIC; different steps in the cycle by which tumors escape immunosurveillance are likely to be different patient by patient. Therefore, we propose to construct an immunogram for each patient in order to better understand the individual patient's CIC and to clarify the steps at which the anticancer response is blocked. In the present study, we defined the immunogram for the CIC by using nextgeneration sequencing data and were able to visualize the status of potential antitumor immune responses within the tumor. When this immunogram is utilized, the landscape of the tumor microenvironment in each patient can be appreciated and the compromised steps of the CIC can be easily visualized.
Immunograms of patients with lung cancer have several characteristics in common, reflecting their gene signatures relevant to T-cell responses (IGS 1 ). In patients with a T-cell-rich phenotype, high scores for IGS 3 , IGS 4 , and IGS 5 and low scores for IGS 6 , IGS 7 , and IGS 8 were found to be typical (see Fig. 5A and D) . This suggests that the tumor microenvironment is dominated by inhibitory cell infiltration and the expression of checkpoint and immunoinhibitory molecules that counterregulate antitumor immune responses. For example, the immunogram of patient LK071 with a T-cell-rich phenotype demonstrated that T-cell immunity potentially existed in the tumor but was suppressed by inhibitory cells and molecules, including checkpoint molecules (see Fig. 5A ). Upon reviewing the transcriptomic data for this patient, we hypothesize that IDO1 may be one of the key molecules in this respect (see Fig. 4D ). Therefore, strategies to unleash T-cell responses by depleting immunosuppressive cells, immune checkpoint blockade, or enzymatic inhibition of the immunosuppressive molecules might be recommended for this patient (Fig. 6) .
In contrast, low scores for IGS 3 , IGS 4 , and IGS 5 and high scores for IGS 6 , IGS 7 , and IGS 8 were common features of the immunogram in patients with a T-cell-poor phenotype (see Fig. 5C and D) . Lack of induction of antitumor immunity in these patients might have been due to inadequate DC activation or insufficient antigen processing and presentation in the tumor. The lack of recruitment of immunosuppressive cells and absence of expression of immune checkpoint and immunoinhibitory molecules also reflects the lack of induction of counterregulatory immunosuppression in the tumor. On the basis of inspection of the immunograms, it would be predicted that immune checkpoint blockade would be unlikely to be effective for these T-cell-poor patients. For example, the immunogram of patient LK073 with a T-cell-poor phenotype demonstrated that although a certain amount of cancer antigen was detected, DC activation was significantly impaired (see Fig. 5C ). For this patient, intervention to enhance T-cell trafficking into tumors such as through the induction of immunogenic cell death by chemotherapy or radiotherapy or through the direct activation of DCs by neoantigen-targeted vaccines might be a preferred therapeutic option 29, 30 (see Fig. 6 ). The hierarchical clustering using each z scores for IGS (see Figs. 2, 3 , and 4) also displayed two clusters of patients: a cluster that contained all T-cell-rich patients and another cluster that contained all T-cell-poor patients (Supplementary Data 9 [ Supplementary Fig. 3 ], the result of hierarchical clustering using z scores for IGS). In addition, IGS axes were clustered into two groups: a cluster associated with immunological status of T cells and another cluster regarding antigens and antigen presentation of the tumor.
In the present study, IGS 2 was generally low in tumors with a T-cell-rich phenotype, especially owing to their lower neoantigen load. This may be partly explained by cancer immunoediting (by the fact that subclones of tumor cells expressing immunogenic antigens are more likely to be eliminated by the T-cell immunity in these patients). 12, 16 This may also suggest that T cells can nonetheless be recruited by only a few effective neoantigens, and it also implies that T cells will not be recruited even by abundant neoantigens if certain other steps of the CIC are compromised. Hence, non-T-cellinflamed tumors with abundant neoantigens might be suitable targets for neoantigen-based vaccine therapy. In the case of patients LK070, LK001, and LK044, reduced expression of antigen-presenting machinery was observed in the presence of abundant tumor-infiltrating T cells, suggesting that T cells might not adequately recognize tumor cells (see Figs. 4B and 5A ). Interventions to up-regulate major histocompatibility complex expression, such as epigenetic therapy, or alternative interventions, such as chimeric antigen receptor cell therapy (which does not depend on major histocompatibility complex class I antigen presentation for recognition of antigens), might be required in these cases. 31, 32 Interestingly, when we overlaid the immunograms for adenocarcinoma with or without EGFR mutation and a nonadenocarcinoma tumor, no typical pattern for each tumor type emerged (see Fig. 5E ). Both T-cell-inflamed and non-T-cell-inflamed phenotypes were present in each histologic type. These results are consistent with previous studies showing that clinical responses on checkpoint blockade were not easily predicted by the histologic type of the tumor.
3-5 When we overlaid the immunograms by age, sex, and smoking status, a similar pattern with relatively low antigenicity (IGS 2 ) was observed in female and never-smoking patients (Supplementary Data 10 [ Supplementary Fig. 4]) . Generally, EGFR mutation is related to female sex and never-smoking status. 33 Never-smoking status is related to lower mutational load. 34 Thus, patients with EGFR mutation-positive adenocarcinoma, female sex, and never-smoking status are overlapped, resulting in a similar immunogram pattern of lower mutational burden. These results support the findings that an immunogram of each patient successfully reflects the patient's immunological status and background.
We propose that the application of the immunograms for the CIC in each patient will be beneficial for tailoring personalized immunotherapy. One of the advantages of integrative analysis of multiple genes is that it may increase the reliability of gene expression data with low levels of expression. However, there are several limitations to the present study. First, immunogram axes and each gene list are not absolutes and should be altered along with advances in knowledge and technologies. Although the presented immunogram depicts the landscape of cancer immunity in each patient, there are many other factors related to T-cell dysfunction, such as abnormal tumor metabolism, that may also play a role. Inclusion of these factors may strengthen prediction of the effectiveness of cancer immunotherapy. Second, not only neoantigens and CG antigens act as tumor antigens. There are still many other types of cancer antigens that cannot be found from exome data or classical expression analysis, for example, viral antigens from oncoviruses, or abnormal expression of human endogenous retroviral antigens. 16, 18 Third, although the immunogram may precisely depict a complicated immune status, it is a snapshot of only that moment in time. Thus, for example, if T-cell immunity could be induced in the T-cell-poor tumor by an appropriate treatment (e.g., induction of immunogenic cell death by chemoradiotherapy, neoantigen vaccines, anti-CTLA4 antibody, interferon-a agent, CD40 agonist, and manipulation of microbiota for enhancement of DC activation), 9, 35, 36 then counterregulatory checkpoint molecule expression and induction or recruitment of inhibitory cells and inhibitory molecules might follow. Reevaluation of the patient's immunological status would be required to monitor this. Combinations of several modalities of therapy might then be recommended according to updated immunograms (see Fig. 6 ). Finally, because of the small number of patients included in the present study, we could not offer the complete panorama of immune landscape in patients with lung cancer. Further accumulation of patient data, including treatment outcome, is crucial for making an optimal immunogram that could appropriately determine the best treatment combinations and strategies for every patient with lung cancer.
Despite these limitations, the scoring and visualization of the cancer-immunity status of each patient using the immunogram may yield a better understanding of cancer-immunity interactions than does current data management relying on restricted information with IHC and limited amounts of gene expression data. The immunogram for the CIC may thus represent a promising tool for translating cumbersome omics data into easily comprehensible "report cards" for clinicians to use to tailor optimal immunotherapy for each patient.
In conclusion, comprehensive understanding of cancer-immunity interactions is essential for providing effective cancer immunotherapy. The immunogram for the CIC can be used as an integrated biomarker, providing us with a clearer view of the landscape of cancer-immunity interaction status in each patient, and it may thus become a valuable resource for personalized immunotherapy.
